VJHemOnc is committed to improving our service to you

COMy Virtual 2020 | Targeting SLAMF7 in myeloma

VJHemOnc is committed to improving our service to you

Katja Weisel

Katja Weisel, MD, University Medical Center Hamburg-Eppendorf, Hamburg, Germany, discusses elotuzumab, a monoclonal antibody targeting SLAMF7, in relapsed/refractory multiple myeloma. Additionally, Dr Weisel reveals that SLAMF7 is an important target for CAR T-cell therapy. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter